Clinical Trial: Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07007806) titled 'Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir' on May 19.

Brief Summary: Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteer Study

Intervention: DRUG: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

On day 1 single 550 mg/180 mg dose BEM/RZR FDC (2 x 275 mg/90 mg FDC tablets) will be administered under fasting conditions.

DRUG: Treatment B-Omeprazole 20 mg dose administered fasting

On Day 4 to Day 13, a 20 mg dose omeprazole (1 x 20 mg) will be administered QD under fasting c...